Welcome to the Future of Precision Oncology – Join Us in Wilmington, DE! We’re thrilled to announce the launch of our cutting-edge Antibody Drug Conjugate (ADC) manufacturing facility in Wilmington, Delaware—a bold step forward in transforming cancer care through innovation, collaboration, and purpose-driven science. ADCs represent one of the most exciting frontiers in biopharmaceuticals today. By combining the targeting power of monoclonal antibodies with the potency of cytotoxic drugs, ADCs deliver cancer-killing agents directly to tumor cells, minimizing damage to healthy tissue. This precision has revolutionized treatment for hematologic malignancies and is rapidly expanding into other cancers. The global ADC market is booming, projected to surpass $16 billion in 2025 and grow steadily through 2035. Innovations in linker technology, payload design, and AI-driven antibody optimization are accelerating breakthroughs and expanding therapeutic possibilities. Our Wilmington facility is designed to meet the growing demand for high-potency manufacturing, ensure supply chain resilience, and support the next wave of ADC launches. Importantly, this site will support both drug substance conjugation and drug product. As a member of the Wilmington Biotech site leadership team, the Director of Maintenance will lead and oversee all maintenance operations for our sterile product manufacturing facility. This role is critical in ensuring the reliability, safety, and efficiency of all equipment and systems while adhering to strict regulatory standards and best practices in the pharmaceutical industry. The ideal candidate will possess extensive experience in engineering and facilities management, particularly in sterile environments, and will demonstrate strong leadership capabilities to drive continuous improvement initiatives. This position will also have oversight and accountability for integrated facilities management (IFM) for the site.